MRK.DE - MERCK Kommanditgesellschaft auf Aktien

XETRA - XETRA Delayed price. Currency in EUR
117.90
+0.30 (+0.26%)
As of 9:24AM CET. Market open.
Stock chart is not supported by your current browser
Previous close117.60
Open118.65
Bid117.95 x 6700
Ask117.95 x 11200
Day's range117.75 - 118.30
52-week range85.84 - 118.90
Volume30,670
Avg. volume463,967
Market cap51.26B
Beta (5Y monthly)0.52
PE ratio (TTM)14.82
EPS (TTM)7.96
Earnings date05 Mar 2020
Forward dividend & yield1.25 (1.04%)
Ex-dividend date29 Apr 2019
1y target estN/A
  • Does MERCK Kommanditgesellschaft auf Aktien's (ETR:MRK) CEO Pay Matter?
    Simply Wall St.

    Does MERCK Kommanditgesellschaft auf Aktien's (ETR:MRK) CEO Pay Matter?

    Stefan Oschmann became the CEO of MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) in 2016. This report will, first...

  • Is MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) A Great Dividend Stock?
    Simply Wall St.

    Is MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) A Great Dividend Stock?

    Is MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) a good dividend stock? How can we tell? Dividend paying companies...

  • Palantir Wins New Pentagon Deal With $111 Million From the Army
    Bloomberg

    Palantir Wins New Pentagon Deal With $111 Million From the Army

    (Bloomberg) -- The U.S. Army will spend $111 million next year in a new contract with Palantir Technologies Inc., deepening ties between Peter Thiel’s data analytics company and the Pentagon.The new Defense Department deal will represent about 10% of Palantir’s revenue next year, according to people familiar with the company’s finances. It’s the first step in what could be a four-year, $440 million deal with the Army.The Silicon Valley company will provide software to connect human resources, supply chains and other Army operations systems into a single dashboard. The Army considered earlier proposals for related work from Accenture Plc, Deloitte, Ernst & Young and Microsoft Corp.“We started Palantir in 2004 to help the war fighter and solve difficult problems,” Doug Philippone, head of Palantir’s global defense business, said in an emailed statement. “In helping the Army make better use of its own data, we accomplish both goals.”The Defense deal solidifies a relationship between the U.S. government and the Palo Alto, California-based company, which was co-founded and partly bankrolled by Thiel. The billionaire venture capitalist and adviser to President Donald Trump has chastised other technology companies, in particular Alphabet Inc.’s Google, for their reluctance to work with the Defense Department. After Google abandoned a Pentagon effort known as Project Maven, Palantir stepped in to help develop video recognition software as part of the project, a move reported earlier by Business Insider.On Saturday, a company spokeswoman said Palantir will run its first-ever commercials, which will air during the Army-Navy football game, in a bid to show its support for the U.S. military.In recent years, Palantir has sought to work more with companies and be less reliant on government contracts. Airbus SE and Merck KGaA are among its customers, but government clients still make up a significant portion of revenue.To contact the reporter on this story: Lizette Chapman in San Francisco at lchapman19@bloomberg.netTo contact the editors responsible for this story: Mark Milian at mmilian@bloomberg.net, Anne VanderMeyFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Thiel Marks Palantir’s Asia Push with $150 Million Japan Venture
    Bloomberg

    Thiel Marks Palantir’s Asia Push with $150 Million Japan Venture

    (Bloomberg) -- In a rare show of public support, Palantir Technologies Inc.’s co-founder and chairman Peter Thiel pitched the power of the data-mining company during a splashy Tokyo event marking its formal entry into Asia.The billionaire entrepreneur was in Japan Monday to unveil a $150 million, 50-50 joint venture with local financial services firm Sompo Holdings Inc., Palantir Technologies Japan Co. The new company will target government and public sector customers, emphasizing health and cybersecurity initially. Like IBM Corp. and other providers, Palantir’s software pulls together a range of data provided by its customers, mining it for patterns and displaying connections in easy-to-read spiderweb-like graphics that might otherwise get overlooked.“We can learn a lot from Japan, that some of the challenges that Japan has with its aging population are the ones all countries of the West are going to have in the years ahead,” Thiel said at a briefing in Tokyo. “We hoped this can be a two-way exchange.”The push into Asia comes at a critical time for the 15-year-old company. Despite having long-term, billion-dollar contracts with BP Plc., Merck KGaA and others in more than a dozen countries worldwide, Palantir has never turned an annual profit. Under the leadership of Thiel and the management of Chief Executive Officer Alex Karp, Palantir has long emphasized engineering over sales and revenue, a focus that has shifted only this year.The company has not set a date for an initial public offering and continues to explore raising additional funding from private investors. Palantir spokeswoman Lisa Gordon told Bloomberg there are no formal conversations underway and disputed reports that Palantir is considering a deal with Softbank Group Corp. or that the company is seeking as much as $3 billion in funding at a $30 billion valuation.Valuation is a touchy subject for the Silicon Valley company. Although private investors valued Palantir in 2015 at more than $20 billion, aggressive markdowns by mutual funds and an uncertain IPO timeline have taken a toll. Palantir’s valuation has continued to tumble, with shares trading around $5 a share during the past month, according to data from secondary markets.Palantir is very close to breaking even and will end 2019 either slightly in the black or slightly in the red, Thiel said at the briefing. The company will be “significantly in the black” next year, he added.“The judgment call Palantir has made, as have many other companies in Silicon Valley post 2000, is it is often much better to build businesses in private,” Thiel said. “There is some day in the future when Palantir will go public, but we will try to stay private as long as possible.”Palantir’s public image has taken a beating in recent years. It’s attracted scrutiny from privacy advocates and protesters disturbed by the way Palantir’s software has been used by state and local law enforcement in the U.S., as well as by federal agencies like the Department of Homeland Security while implementing the controversial family separation policy at the U.S. Mexican border.Thiel himself has been a lightning rod for criticism, having helped the election of U.S. President Donald Trump in 2016, a divisive decision even within Palantir. That critique could intensify given he has pledged to support Trump’s 2020 re-election.“I envision supporting President Trump over his likely Democratic nominees,” Thiel said in Tokyo, adding he will determine the exact nature of his support as elections approach.(Updates with comments from news briefing from the third paragraph.)To contact the reporters on this story: Pavel Alpeyev in Tokyo at palpeyev@bloomberg.net;Lizette Chapman in San Francisco at lchapman19@bloomberg.netTo contact the editors responsible for this story: Edwin Chan at echan273@bloomberg.net, Vlad SavovFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Merck KGaA raises 2019 guidance after Versum takeover
    Reuters

    Merck KGaA raises 2019 guidance after Versum takeover

    German science and technology company Merck KGaA raised its full-year forecast for sales and adjusted earnings on Thursday after completing the takeover of semiconductor materials maker Versum Materials in October. Merck said 2019 earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for special items, would come in between 4.23 billion euros and 4.43 billion euros (£3.82 billion), up from a previous prediction of between 4.15 billion euros and 4.35 billion euros. Shares in Merck were down 1.55% at 0828 GMT.

  • If You Had Bought MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Stock Five Years Ago, You Could Pocket A 47% Gain Today
    Simply Wall St.

    If You Had Bought MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Stock Five Years Ago, You Could Pocket A 47% Gain Today

    Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the...

  • Calculating The Intrinsic Value Of MERCK Kommanditgesellschaft auf Aktien (ETR:MRK)
    Simply Wall St.

    Calculating The Intrinsic Value Of MERCK Kommanditgesellschaft auf Aktien (ETR:MRK)

    Today we'll do a simple run through of a valuation method used to estimate the attractiveness of MERCK...

  • These 4 Measures Indicate That MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Is Using Debt Reasonably Well
    Simply Wall St.

    These 4 Measures Indicate That MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Is Using Debt Reasonably Well

    David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

  • Reuters - UK Focus

    Merck KGaA lung cancer drug is 3rd on U.S. watchdog's priority lane

    Merck KGaA's prospective lung cancer treatment tepotinib became the third drug against a rare and aggressive subtype of the disease that won U.S. Food and Drug Administration's breakthrough therapy designation. Novartis last week won the breakthrough therapy tag, which puts it on a fast track for regulatory review, for its capmatinib drug. Pfizer's Xalkori drug was given the designation https://www.pfizer.com/news/press-release/press-release-detail/pfizer_s_xalkori_crizotinib_receives_fda_breakthrough_therapy_designation_in_two_new_indications-0 last year.

  • These 4 Measures Indicate That MERCK Kommanditgesellschaft auf Aktien (FRA:MRK) Is Using Debt Reasonably Well
    Simply Wall St.

    These 4 Measures Indicate That MERCK Kommanditgesellschaft auf Aktien (FRA:MRK) Is Using Debt Reasonably Well

    Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...

  • Reuters - UK Focus

    UPDATE 2-GSK builds oncology pipeline as drug shown to help myeloma patients

    GlaxoSmithKline said an experimental multiple myeloma treatment has shown a meaningful response in patients that have run out of three previous treatment options, in a boost for the British drugmaker's cancer drug business. Two doses of belantamab mafodotin helped subdue the disease in adults who had received three prior treatments for multiple myeloma, a cancer of the white blood cells, GSK said on Friday. GSK sold its approved oncology drugs to Novartis in 2014, but has staged a comeback in cancer treatment with a deal to buy U.S. firm Tesaro for $5.1 billion last year and an agreement in February to pay up to 3.7 billion euros ($4.09 billion) to Germany's Merck KGaA for the rights to a next-generation immunotherapy.

  • Reuters - UK Focus

    No-deal Brexit could deepen Europe's shortage of medicines - experts

    As the Oct. 31 deadline for Britain to leave the European Union approaches, health professionals are warning that shortages of some medicines could worsen in Europe in the event of a no-deal Brexit. Britain's food and drink lobby warned last week that the country would experience shortages of some fresh foods if there is a disorderly no-deal Brexit.

  • Reuters - UK Focus

    UPDATE 2-GSK drug helps ovarian cancer patients live longer in late-stage study

    GlaxoSmithKline Plc's cancer treatment Zejula met the main goal of helping patients with ovarian cancer live longer without their disease worsening in a late-stage study, the company said on Monday. The company bought the drug when it acquired U.S. cancer specialist Tesaro for $5.1 billion in December and Zejula is already approved for certain ovarian cancer patients. For GSK, the success of Zejula would help it access a wider population group and give it an edge over rival PARP inhibitors such as AstraZeneca and Merck & Co's Lynparza and Clovis Oncology's Rubraca.

  • Despite Its High P/E Ratio, Is MERCK Kommanditgesellschaft auf Aktien (FRA:MRK) Still Undervalued?
    Simply Wall St.

    Despite Its High P/E Ratio, Is MERCK Kommanditgesellschaft auf Aktien (FRA:MRK) Still Undervalued?

    This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios...

  • How Does MERCK Kommanditgesellschaft auf Aktien (FRA:MRK) Fare As A Dividend Stock?
    Simply Wall St.

    How Does MERCK Kommanditgesellschaft auf Aktien (FRA:MRK) Fare As A Dividend Stock?

    Could MERCK Kommanditgesellschaft auf Aktien (FRA:MRK) be an attractive dividend share to own for the long haul...

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more